Centene stock hits 52-week low at $27.33 amid challenging year

Published 24/07/2025, 17:22
Centene stock hits 52-week low at $27.33 amid challenging year

Centene (NYSE:CNC) Corp’s stock reached a 52-week low, hitting $27.33, with the healthcare giant’s market capitalization now standing at $13.64 billion. According to InvestingPro analysis, the stock appears undervalued, trading at a modest P/E ratio of 4.06 despite generating substantial revenue of $153.27 billion. Over the past 12 months, Centene’s stock has experienced a sharp 59.39% decrease, reflecting investor concerns and broader market pressures affecting the healthcare sector. This downturn highlights the ongoing challenges Centene is navigating, including regulatory changes and competitive pressures, which have contributed to its current stock performance. Despite these challenges, InvestingPro data shows the company maintains a GREAT financial health score, with technical indicators suggesting oversold conditions. As the company continues to strategize for future growth, market watchers will be keen to see how Centene addresses these hurdles in the coming months. For deeper insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering this prominent healthcare provider.

In other recent news, Centene Corporation has faced a series of downgrades from major financial firms. TD Cowen downgraded Centene from Buy to Hold, citing concerns over multiple service lines, including Medicaid, Health Insurance Exchange (HIX), and Prescription Drug Plan operations. Similarly, BofA Securities downgraded Centene to Underperform, highlighting concerns about slowing end markets in Medicaid and Affordable Care Act exchanges, which together account for a significant portion of Centene’s revenue. Morgan Stanley (NYSE:MS) also downgraded the company, noting pressure in the HIX business due to data that differed from the company’s expectations.

Additionally, Centene has withdrawn its 2025 financial guidance due to significant challenges in its Marketplace business and emerging Medicaid issues. Preliminary data indicated a higher market morbidity on the Exchanges than anticipated, leading to an estimated $1.8 billion reduction in expected risk adjustment revenue transfers. This adjustment is anticipated to impact earnings per share by $2.75. Meanwhile, Canada Nickel Company announced positive exploration drilling results at its MacDiarmid property, identifying extensive mineralization. The drilling program has extended the strike length to approximately 2,200 meters and a width of about 400 meters.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.